Anti-RSV F Glycoprotein [11-2-C9]
Invented by Ayham Alnabulsi from Vertebrate Antibodies Limited
Invented at Vertebrate Antibodies Limited
- Datasheet
- References (6)
- Inventor Info
Info
![Image thumbnail for Anti-RSV F Glycoprotein [11-2-C9]](https://res.cloudinary.com/ximbio/image/upload/c_fit,fl_lossy,h_45,q_auto/93326c67-2874-4846-bda9-98a1dc16237b.jpg)
| Catalogue Number | 151856 |
| Applications | ELISA IF Fn WB |
| Antigen/Gene or Protein Targets | Human Respiratory Syncytial (RS) virus Fusion glycoprotein |
| Reactivity | Virus |
| Relevance | Human Respiratory Syncytial Virus (RSV) is a major cause of lower respiratory tract illness and is the chief cause of hospitalization for respiratory tract illness in young children.The glycoprotein F is located on the surface of viral envelope, its function is to induce fusion of viral envelope with host-cell envelope resulting in syncytium formation. The glycoprotein F (also named VP70, F0 or fusion protein) consists of two components: F1 (also named VPG48) and F2 (also named VGP26) held together by disulphide bonds. The reported molecular weight of the VGP26 component varies between 20 to 26 kDa. |
| Host | Mouse |
| Immunogen | Gradient-purified RSF-44 virus (subgroup A) UV inactivated for 20 minutes at 20C |
| Positive Control | Immunoblot: Ag: gradient-purified RS virus (see figure). Indirect immunofluorescence: staining of RSA-2 infected BSC-1 cells |
| Subclass | IgG1 kappa |
| Molecular Weight (kDa) | The identity and molecular weight of the protein target of this antibody was validated by including within the immunoblot assay (as a marker) a convalescent serum sample from a RS virus infected patient. The protein specificities of the antibodies induced in the human convalescent serum is described in Gimenez et al. (1987). |
| Myeloma Used | P3X63Ag8.653 |
| Recommended Growing Conditions | Dulbecco’s media containing 20% Foetal Bovine serum and 2mM Glutamine. |
| Strain | Balb/c |
| Notes |
Immunoblot using the reduced and unreduced RS virus shows that 11-2-C9 reacts with the non-reduced form of the virus F protein (VP70). It has a plaque reduction neutralization titer of 10 2. This antibody reacts with the fusion glycoprotein, F (also named VP70 or F0 protein), from both subgroups A and B of RS virus. The 11-2-C9 antibody has RS virus enhancing activity in vitro (enhancement index range: 4.3-5.6) (Gimenez et al., 1996). |
| Research Area | Virology |
References: 6 entries
Gimenez et al. 1996. Clin Diagn Lab Immunol. 3(3):280-6. PMID: 8705669.
Neutralizing and enhancing activities of human respiratory syncytial virus-specific antibodies.
Europe PMC ID: 8705669
Gimenez et al. 1986. J Gen Virol. 67 ( Pt 5):863-70. PMID: 3517224.
Fn
Antigenic variation between human respiratory syncytial virus isolates.
Europe PMC ID: 3517224
Gimenez et al. 1984. J Gen Virol. 65 ( Pt 5):963-71. PMID: 6202832.
Monoclonal antibodies to human respiratory syncytial virus and their use in comparison of different virus isolates.
Europe PMC ID: 6202832
Add a reference
References: 6 entries
Gimenez et al. 1996. Clin Diagn Lab Immunol. 3(3):280-6. PMID: 8705669.
Neutralizing and enhancing activities of human respiratory syncytial virus-specific antibodies.
Gimenez et al. 1986. J Gen Virol. 67 ( Pt 5):863-70. PMID: 3517224.
Fn
Antigenic variation between human respiratory syncytial virus isolates.
Gimenez et al. 1984. J Gen Virol. 65 ( Pt 5):963-71. PMID: 6202832.
Monoclonal antibodies to human respiratory syncytial virus and their use in comparison of different virus isolates.
Add a reference
